Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Salbutamol HFA-152a vs HFA-134a in Mild Asthma
NCT06433921Phase 1Recruiting
- Sponsor
- GSK
- Start
- Aug 2024
- Primary completion
- Feb 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of salbutamol in asthma (2 arms), sponsored by GSK. Primary endpoint: Provocative concentration of methacholine causing at least a 20% fall in FEV1 up to 11 weeks. Started Aug 2024; status: recruiting.
02
Drugs
salbutamol
03
Conditions
asthma
Beyond the preview
Go deeper on NCT06433921.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06433921.